Table 1.

Patient characteristics

		Pretreatment lymphocyte count
		Value or no. of patients (%)
Characteristic	All patients	TLC <2.4×103/μL	TLC ≥2.4×103/μL	P-value
	(n=267)	(n=132)	(n=135)
Demographics
Gender
Male	146	74	72	0.654
Female	121	58	63
Age
Median (IQR), years	62(58–71)	63(59–70)	62(60–71)	0.851
KPS score
60–80	234	113	121	0.283
≥80	33	19	14
Smoking status
Current	92	43	49	0.088
Former	151	72	79
Never	24	17	7
Treatment
Radiation technique
3D-CRT	101	49	52	0.814
IMRT	166	83	83
Chemotherapy
No induction chemo	157	77	80	0.879
Induction chemo	110	55	55
No concurrent chemo	70	36	34	0.698
Concurrent chemo	197	96	101
T status
T1	31	15	16	0.494
T2	72	34	38
T3	70	37	33
T4	88	45	43
Tx	9	4	5
N status
N0	50	23	27	0.905
N1	38	19	19
N2	100	52	48
N3	79	38	41
Disease stage
IIIA	58	27	31	0.641
IIIB	209	105	104
Pretreatment laboratory findings
Hb, median (IQR), g/dL	12.9 (12.0–14.4)	12.9 (12.1–14.4)	12.9 (12.0–14.3)	0.047
WBC, median
(IQR), ×103/μL	7.6 (6.3–8.9)	6.8 (5.5–8.3)	8.4 (7.5–9.6)	<0.001
Neutrophils, median
(IQR), ×103/μL	4.8 (3.7–5.9)	4.4 (3.4–5.9)	5.1 (4.2–6.1)	0.063
Platelets, median
(IQR), ×103/μL	249 (201–316)	245 (197–304)	262 (217–334)	0.189

Abbreviations: 3D-CRT, 3-dimensional conformal radiation therapy; Hb, hemoglobin; IMRT, intensity-modulated radiation therapy; IQR, interquartile range; KPS, Karnofsky Performance Status; TLC, total lymphocyte count; WBC, white blood cells.